# Effect of Xolair on Airway Hyperresponsiveness

> **NCT00208234** · PHASE4 · UNKNOWN · sponsor: **Creighton University** · enrollment: 22 (estimated)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** Placebo for Omalizumab
- **DRUG:** omalizumab

## Key facts

- **NCT ID:** NCT00208234
- **Lead sponsor:** Creighton University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-01
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2011-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00208234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00208234, "Effect of Xolair on Airway Hyperresponsiveness". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00208234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*